First Online: 8 October 2014
Change Date: 12 October 2017
Change Type: Correction
Change Details: On page 768 of the article, the text has been changed to clarify that all vaccinated and control animals were challenged until documentation of SIV infection by virological and/or immunological criteria. Furthermore, on page 768, the text has been changed to specify both the number of vaccinated controllers shown in Figure 2 after intrarectal challenge as well as the number of controllers after both intrarectal and intravaginal challenge. Finally, the legend of Figure 2 has been changed to clarify that the graph shows intrarectal SIVmac239 challenge of monkeys that have either been vaccinated twice with a strain 68-1 RhCMV/SIV vector (week 0 and week 14; n = 36) or once with these vectors (week 0) and were then vaccinated at week 14 with Ad5 vectors (n = 12). Changes have been made to both the HTML and PDF versions of the article. The authors apologize to readers for any confusion caused.
: L.J.P and Oregon Health and Science University (OHSU) have a significant financial interest in TomegaVax, Inc., which is a company that may have a commercial interest in the results of this research and technology. The potential individual and institutional conflicts of interest have been reviewed and managed by OHSU. D.H.B. is a named co-inventor on various vector and antigen patents.
Free to read: This content has been made available to all.